

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Felix Lourdes</u> (Last) (First) (Middle) 2390 EAST ORANGEWOOD SUITE 570 (Street) ANAHEIM CA 92806 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BioCorRx Inc. [BICX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;">CEO and CFO</p>
	3. Date of Earliest Transaction (Month/Day/Year) 04/24/2024	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value \$0.001	04/24/2024		A ⁽¹⁾		224,196	A	\$0	314,795	D	
Common Stock, par value \$0.001	07/02/2024		A ⁽²⁾⁽³⁾		500,000	A	\$0	814,795	D	
Common Stock, par value \$0.001	09/30/2024		A ⁽⁴⁾		15,625	A	\$0	830,420	D	
Common Stock, par value \$0.001	12/31/2024		A ⁽⁵⁾		13,158	A	\$0	843,578	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

- These shares were issued to Ms. Felix pursuant to an Exchange Agreement (the "April 2024 Exchange Agreement") by and between BioCorRx Inc. (the "Company") and Ms. Felix dated April 24, 2024. Pursuant to the April 2024 Exchange Agreement, Ms. Felix agreed to the exchange of directors fees in the amount of \$265,000 for 224,196 shares of the Company's common stock, par value \$0.001 per share (the "Common Stock") at a price of \$1.18 per share based on the underlying value of the Common Stock at the date of issuance.
- These shares were issued to Ms. Felix pursuant to a Stock Grant Award Agreement (the "Award Agreement") by and between the Company and Ms. Felix, dated July 2, 2024. Pursuant to the Award Agreement, in recognition of Ms. Felix's services to the Company, and for assuming additional responsibilities, the Company issued 500,000 shares of Common Stock to Ms. Felix, representing an amount equal to \$235,000, or \$0.32 per share based on the closing price of the Common Stock on the date of issuance. These shares are subject to lock-up obligations for a period of 180 days following the date on which the Company's securities become listed for trading on a national securities exchange.
- These shares are subject to lock-up obligations for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act of 1933, as amended, pursuant to which the Company's securities become listed for trading on a national securities exchange or such longer period to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation.
- These shares were issued to Ms. Felix pursuant to a Director Agreement (the "Director Agreement"), dated March 1, 2019, by and between the Company and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to \$5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was \$0.32.
- These shares were issued to Ms. Felix pursuant to the Director Agreement. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to \$5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was \$0.38.

Remarks:

/s/ Lourdes Felix

01/31/2025

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.